# DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation

> **NCT00083915** · PHASE3 · COMPLETED · sponsor: **University of Arkansas** · enrollment: 97 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Cyclophosphamide
- **DRUG:** Adriamycin
- **DRUG:** Etoposide
- **DRUG:** Melphalan
- **DRUG:** Thalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT00083915
- **Lead sponsor:** University of Arkansas
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-06
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2017-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00083915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00083915, "DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00083915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*